Showing results (171-180 of 209) with videos related to
Sort By:
Pageof 21
Alzheimer'S Research & Therapy|August 1, 2018
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's diseaseCraig W Ritchie, Tom C Russ, Sube Banerjee, et al.Journal of Alzheimer'S Disease : JAD|February 8, 2011
A multi-center study of ACE and the risk of late-onset Alzheimer's diseaseOlivia Belbin, Kristelle Brown, Hui Shi, et al.Brain : a Journal of Neurology|September 11, 2019
CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S miceRenzo Mancuso, Gemma Fryatt, Madeleine Cleal, et al.The Lancet. Psychiatry|April 19, 2020
Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health scienceEmily A Holmes, Rory C O'Connor, V Hugh Perry, et al.The British Journal of Psychiatry : the Journal of Mental Science|December 22, 2012
Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trialRenee Romeo, Martin Knapp, Jennifer Hellier, et al.Lancet (London, England)|July 19, 2011
Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trialSube Banerjee, Jennifer Hellier, Michael Dewey, et al.Dementia and Geriatric Cognitive Disorders|November 8, 2007
Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part IPauline Aalten, Frans R J Verhey, Marina Boziki, et al.Dementia and Geriatric Cognitive Disorders|November 21, 2007
Consistency of neuropsychiatric syndromes across dementias: results from the European Alzheimer Disease Consortium. Part IIPauline Aalten, Frans R J Verhey, Marina Boziki, et al.Journal of Neurochemistry|June 2, 2016
Targeting innate immunity for neurodegenerative disorders of the central nervous systemKatrin I Andreasson, Adam D Bachstetter, Marco Colonna, et al.International Journal of Geriatric Psychiatry|October 15, 2016
Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial)Martin Knapp, Derek King, Renée Romeo, et al.Pageof 21